Member Info for Laura2022

Can you explain the significant please KingH if you get time

Thanks LSB

Thanks Aberystwyth

I have purchased £1500

It was a buy as Tricky says

08-Aug-2408:01:270.788241,116Buy*1,900O 08-Aug-2408:00:480.78565,866Buy*517.05O 

It's a buy as the ask was 0.79/8 on open and bid 0.76

Please.go away

Thanks Tricky

Another large buy ..someone is building a big stake here this week

That's very kind

We're all in this world altogether..(as shown thankfully last night across Britain where communities came together)

Welcome

Would eplzpect larger delayed buys later

This is severely undervalued at current MC.

Even at 2p (4 Million MC) its still a steal....lots of news to come to build from here.

* Highest Level of Revenue going into financial year £600k (We are 2 months into it)

* Dosemerx update & Collab

* NHS Prostate Cancer Trial ongoing - update due

* Beyond Blood Trial ongoing - update due (i would suggest people look at the shareholders on this one) Companies House

* Bicycle Therapeutics Update due - to be announced in September

* New Revenue Arm launched

* New Recruit has moved from AstraZeneca

* VAL 201 (Up to £6mil) if that ever ever ever happens who knows....

Apart from the pyc/sar historic connection I know very little about SAR, hence me asking

Don't judge people by your own standards please

You would then think there would be items of news during Aigust to then update at the meeting King H ?

Brilliant summary thanks Kingh

Morning to you also Reb

Please learn some manners

Mrcalm

Try to act like your name lol

You've only been here for a day lol

L x

Exactly Gb

Pyc first started work with Sevier 8th April 2022

Physiomics will be providing specialist mathematical modelling services using its Virtual Tumour software platform to model and simulate the effect of a number of immuno-oncology combinations involving Servier drugs in development in pre-clinical and clinical settings.  It is anticipated that the project will be completed over the course of the next 7-8 months.

 

Physiomics CEO, Dr Jim Millen, commented: “We are delighted to have been selected by Servier, one of France’s leading pharmaceutical companies with a truly global outlook as its partner for this modelling and simulation project focused on pre-clinical and translational modelling of a novel immuno-oncology agent in development.  We look forward to working with its talented scientists.”

6th August 2024

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vorasidenib-grade-2-astrocytoma-or-oligodendroglioma-susceptible-idh1-or-idh2-mutation

As Debull showed yesterday with the PYC re tweet (see 9.30pm last night ) PYC don't just mention this for nothing ( see also their Sheff Uni tweet)

Everything mentioned in the AZN tweet is what PYC have been working on and highlighting for the last 18mths namely

Using A.i/mathematical modelling in drug development

Good morning

I am looking to buy SAR as it looks like some latter buying is going on this ladt 3 days or so , apart from this below could be kind enough to say ehat else is expected this year..many thanks

The Company expects that further data, unblinded from drug/placebo recipients, including details of any mild or moderate adverse events and biomarkers of TYK2 and/or JAK1 inhibition, will be available in Q3 2024.

Morning GB

It's great more people are aware of this A.i bio tech as sometimes that's all that is needed

The new Ceo here has made much needed changes to the direction and I think Aug/Sept will see plenty of updates